| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 11,690 | 9,760 | 11,960 | 4,340 | 9,390 |
| Sales Growth | +19.77% | -18.39% | +175.58% | -53.78% | +62.46% |
| Net Income | -38,490 | -41,300 | -47,450 | -52,610 | -33,810 |
| Net Income Growth | +6.80% | +12.96% | +9.81% | -55.60% | +12.27% |
Jaguar Health Inc (JAGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its product pipeline consists of Mytesi(R), Canalevia(TM), Equilevia(TM) and Neonorm (TM). Jaguar Health Inc., formerly known as Jaguar Animal Health Inc., is based in San Francisco, United States.
Fiscal Year End Date: 12/31